Hormonal Manipulation with Finasteride or Oral Contraception Does Not Influence Incidence of Renal Cell Carcinoma
| Autor: | Michael A. Liss, Jonathan Gelfond, Aashish Kabra |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
Cancer Research Lung Neoplasms Epidemiology 030232 urology & nephrology Prostatic Hyperplasia chemistry.chemical_compound 0302 clinical medicine 5-alpha Reductase Inhibitors Renal cell carcinoma Risk Factors Longitudinal Studies Ovarian Neoplasms education.field_of_study Incidence Hazard ratio Finasteride Middle Aged Kidney Neoplasms Contraception Oncology 030220 oncology & carcinogenesis Female Colorectal Neoplasms medicine.medical_specialty Population Article 03 medical and health sciences Internal medicine medicine Humans education Carcinoma Renal Cell Aged Gynecology Proportional hazards model business.industry Public Health Environmental and Occupational Health Cancer Prostatic Neoplasms Dutasteride medicine.disease Confidence interval chemistry Self Report business Contraceptives Oral Follow-Up Studies |
| Popis: | Androgens have been suspected to be involved in the initiation of renal cell carcinoma because of a two-fold increased risk in men compared with women. To investigate the role of self-reported finasteride or oral contraceptive use in the Prostate, Lung, Colorectal, and Ovarian (PCLO) to determine whether the androgen receptor reduces renal cancer development. We query the PCLO trial for predictor variables from the baseline questionnaire and follow-up questionnaires enquiring medication use, specifically the use of 5-α reductase inhibitors (dutasteride or finasteride) and oral contraceptive therapy. The primary outcome of this study was the incidence of renal cancer. Statistical analysis included Student's t-test for continuous variables, χ, or Fisher's exact tests for dichotomous or categorical variables, and multivariable analysis using Cox proportional hazards models. Eight percent (n=6117/73 694) of men in the PCLO trial reported the use of finasteride. 52 (10.6%) of the 492 men diagnosed with renal cancer had self-reported exposure to finasteride and this was not significant in univariable analysis (52/6169; 0.84% vs. 440/66 454; 0.67%, P=0.12) or multivariable main effects analysis (hazard ratio: 1.12; 95% confidence interval: 0.83-1.5; P=0.47). Approximately 54% of women (n=40 997/75 989) in the PCLO trial reported the use of oral contraceptives by questionnaire. 136 (52.1%) of the 261 women diagnosed with renal cancer had self-reported exposure to oral contraceptive therapy and this was not significant in univariable analysis (136/40 997; 0.33% vs. 125/34 992; 0.36%, P=0.36) or in multivariable main effects analysis (hazard ratio: 1.03; 95% confidence interval: 0.97-1.1; P=0.30). Self-reported use of finasteride or oral contraceptives is not associated with a reduced incidence of renal cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|